Literature DB >> 26472946

Understanding Drivers of Employment Changes in a Multiple Sclerosis Population.

Karin S Coyne1, Audra N Boscoe1, Brooke M Currie1, Amanda S Landrian1, Todd L Wandstrat1.   

Abstract

BACKGROUND: Qualitative data are lacking on decision making and factors surrounding changes in employment for patients with multiple sclerosis (MS). This study aimed to increase our understanding of the key symptoms and factors leading patients with MS to leave work or reduce employment.
METHODS: Adults with MS who reported leaving the workforce, reducing work hours, or changing jobs due to MS in the past 6 months were recruited from four US clinical sites. Patients participated in semistructured interviews to discuss MS symptoms and reasons for changing employment status. All interviews were transcribed and coded for descriptive analyses.
RESULTS: Twenty-seven adults (mean age = 46.3 years, mean duration of MS diagnosis = 10.9 years) with a range of occupations participated; most were white (81.5%) and female (70.4%). Physical symptoms (eg, fatigue, visual deficits) (77.8%) were the most common reasons for employment change; 40.7% of patients reported at least one cognitive symptom (eg, memory loss). Fatigue emerged as the most pervasive symptom and affected physical and mental aspects of patients' jobs. Most patients (85.2%) reported at least two symptoms as drivers for change. Some patients reported a significant negative impact of loss of employment on their mental status, family life, and financial stability.
CONCLUSIONS: Fatigue was the most common symptom associated with the decision to leave work or reduce employment and can lead to a worsening of other MS symptoms. Comprehensive symptom management, especially fatigue management, may help patients preserve their employment status.

Entities:  

Year:  2015        PMID: 26472946      PMCID: PMC4599362          DOI: 10.7224/1537-2073.2014-051

Source DB:  PubMed          Journal:  Int J MS Care        ISSN: 1537-2073


  17 in total

1.  The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US.

Authors:  Jasmina I Ivanova; Howard G Birnbaum; Seth Samuels; Matthew Davis; Amy L Phillips; Dennis Meletiche
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

2.  Factors associated with unemployment of patients with multiple sclerosis.

Authors:  N Larocca; R Kalb; L Scheinberg; P Kendall
Journal:  J Chronic Dis       Date:  1985

Review 3.  Supporting work for people with multiple sclerosis.

Authors:  Catherine Doogan; E Diane Playford
Journal:  Mult Scler       Date:  2014-02-13       Impact factor: 6.312

4.  Living with multiple sclerosis: longitudinal changes in employment and the importance of symptom management.

Authors:  Rex D Simmons; Kate L Tribe; Elizabeth A McDonald
Journal:  J Neurol       Date:  2010-01-19       Impact factor: 4.849

5.  Getting the work done: a qualitative study of individuals with multiple sclerosis.

Authors:  Kathryn M Yorkston; Kurt Johnson; Estelle R Klasner; Dagmar Amtmann; Carrie M Kuehn; Brian Dudgeon
Journal:  Disabil Rehabil       Date:  2003-04-22       Impact factor: 3.033

6.  The use of focus groups to characterize symptoms in persons with multiple sclerosis.

Authors:  Pamela K Newland; Florian P Thomas; Marguerite Riley; Louise H Flick; Arleen Fearing
Journal:  J Neurosci Nurs       Date:  2012-12       Impact factor: 1.230

7.  Validity of performance scales for disability assessment in multiple sclerosis.

Authors:  R A Marrie; M Goldman
Journal:  Mult Scler       Date:  2007-07-10       Impact factor: 6.312

8.  Employment status in multiple sclerosis: impact of disease-specific and non-disease-specific factors.

Authors:  Ivonne Krause; Simone Kern; Antje Horntrich; Tjalf Ziemssen
Journal:  Mult Scler       Date:  2013-05-01       Impact factor: 6.312

9.  Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.

Authors:  Jane Castelli-Haley; MerriKay Oleen-Burkey; Merry-Kay A Oleen-Burkey; Maureen J Lage; Kenneth P Johnson
Journal:  Adv Ther       Date:  2008-07       Impact factor: 3.845

10.  The feasibility of collecting information from people with Multiple Sclerosis for the UK MS Register via a web portal: characterising a cohort of people with MS.

Authors:  David V Ford; Kerina H Jones; Rod M Middleton; Hazel Lockhart-Jones; Inocencio Dc Maramba; Gareth J Noble; Lisa A Osborne; Ronan A Lyons
Journal:  BMC Med Inform Decis Mak       Date:  2012-07-18       Impact factor: 2.796

View more
  13 in total

1.  Characterizing Long-term Disability Progression and Employment in NARCOMS Registry Participants with Multiple Sclerosis Taking Dimethyl Fumarate.

Authors:  Amber Salter; Samantha Lancia; Gary Cutter; Robert J Fox; Ruth Ann Marrie; Jason P Mendoza; James B Lewin
Journal:  Int J MS Care       Date:  2021-07-09

2.  Associations of White Matter and Basal Ganglia Microstructure to Cognitive Fatigue Rate in Multiple Sclerosis.

Authors:  Cristina A F Román; Glenn R Wylie; John DeLuca; Bing Yao
Journal:  Front Neurol       Date:  2022-07-04       Impact factor: 4.086

3.  Treatment satisfaction in patients with relapsing-remitting multiple sclerosis initiated on teriflunomide in routine clinical practice: Australian observational data.

Authors:  Todd A Hardy; John Parratt; Heidi Beadnall; Stefan Blum; Richard Macdonell; Roy G Beran; Neil Shuey; Andrew Lee; William Carroll; Cameron Shaw; Richard Worrell; Jana Moody; Mamdouh Sedhom; Michael Barnett; Steve Vucic
Journal:  BMJ Neurol Open       Date:  2022-07-04

4.  Trajectories of sickness absence and disability pension days among people with multiple sclerosis by type of occupation.

Authors:  Astrid R Bosma; Chantelle Murley; Jenny Aspling; Jan Hillert; Frederieke G Schaafsma; Johannes R Anema; Cécile R L Boot; Kristina Alexanderson; Alejandra Machado; Emilie Friberg
Journal:  Mult Scler       Date:  2021-10-06       Impact factor: 5.855

Review 5.  The Berlin Treatment Algorithm: recommendations for tailored innovative therapeutic strategies for multiple sclerosis-related fatigue.

Authors:  Christian Veauthier; Helge Hasselmann; Stefan M Gold; Friedemann Paul
Journal:  EPMA J       Date:  2016-11-24       Impact factor: 6.543

6.  The association of fatigue, pain, depression and anxiety with work and activity impairment in immune mediated inflammatory diseases.

Authors:  Murray W Enns; Charles N Bernstein; Kristine Kroeker; Lesley Graff; John R Walker; Lisa M Lix; Carol A Hitchon; Renée El-Gabalawy; John D Fisk; Ruth Ann Marrie
Journal:  PLoS One       Date:  2018-06-07       Impact factor: 3.240

7.  Salivary IL-1ß as an Objective Measure for Fatigue in Multiple Sclerosis?

Authors:  Katrin Hanken; Carina Sander; Lara Qaiser; Hans-Peter Schlake; Andreas Kastrup; Michael Haupts; Paul Eling; Helmut Hildebrandt
Journal:  Front Neurol       Date:  2018-07-16       Impact factor: 4.003

8.  The effect of self-assessed fatigue and subjective cognitive impairment on work capacity: The case of multiple sclerosis.

Authors:  Gisela Kobelt; Dawn Langdon; Linus Jönsson
Journal:  Mult Scler       Date:  2018-04-17       Impact factor: 6.312

9.  High-intensity interval training and energy management education, compared with moderate continuous training and progressive muscle relaxation, for improving health-related quality of life in persons with multiple sclerosis: study protocol of a randomized controlled superiority trial with six months' follow-up.

Authors:  Nadine Patt; Jan Kool; Ruth Hersche; Max Oberste; David Walzik; Niklas Joisten; Daniel Caminada; Francesca Ferrara; Roman Gonzenbach; Claudio Renato Nigg; Christian Philipp Kamm; Philipp Zimmer; Jens Bansi
Journal:  BMC Neurol       Date:  2021-02-11       Impact factor: 2.474

10.  Quantifying the relationship between increased disability and health care resource utilization, quality of life, work productivity, health care costs in patients with multiple sclerosis in the US.

Authors:  E Jones; J Pike; T Marshall; X Ye
Journal:  BMC Health Serv Res       Date:  2016-07-22       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.